Abstract
Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5056-5058 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 26 |
| Issue number | 19 |
| DOIs | |
| State | Published - Oct 1 2020 |
| Externally published | Yes |
Bibliographical note
Funding Information:This work was partially supported by National Institutes of Health Cancer Center support grant P30 CA006973 (to E. Shenderov and E.S. Antonarakis), Prostate Cancer Foundation Young Investigator Award (to E. Shenderov), Department of Defense grant W81XWH-16-PCRP-CCRSA (to E.S. Antonarakis) and grant W81XWH-19-1-0511 (to E. Shenderov), and the Bloomberg-Kimmel Institute for Cancer Immunotherapy (to E. Shenderov and E.S. Antonarakis).
Funding Information:
E.S. Antonarakis reports grants and personal fees from Janssen, Sanofi, Dendreon, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck, personal fees from Astellas, Pfizer, Amgen, Eli Lilly, and Bayer, and grants from Johnson & Johnson, Genentech, Novartis, and Tokai outside the submitted work, as well as a patent for an AR-V7 biomarker technology issued and licensed to Qiagen. No potential conflicts of interest were disclosed by the other author.
Publisher Copyright:
©2020 American Association for Cancer Research.
